Three IPOs each raised less than $50 million during the shortened holiday week. Two biotechs and one regional bank all priced below their proposed ranges, but finished the week above the IPO price. Last week's IPO activity continues what we saw in the second...read more
Minerva Neurosciences, a clinical-stage biotech developing treatments for central nervous system diseases, raised $33 million by offering 5.5 million shares at $6.00, as expected. Minerva Neurosciences plans to list on the NASDAQ under the symbol NERV. Minerva...read more
Minerva Neurosciences, a clinical-stage biotech developing treatments for central nervous system diseases, lowered the proposed deal size for its upcoming IPO on Monday. The Cambridge, MA-based company now plans to raise $33 million by offering 5.5 million...read more
US IPO Pricing Recap: Three small and discounted deals price before the holiday
Three IPOs each raised less than $50 million during the shortened holiday week. Two biotechs and one regional bank all priced below their proposed ranges, but finished the week above the IPO price. Last week's IPO activity continues what we saw in the second...read more
Minerva Neurosciences prices IPO at $6
Minerva Neurosciences, a clinical-stage biotech developing treatments for central nervous system diseases, raised $33 million by offering 5.5 million shares at $6.00, as expected. Minerva Neurosciences plans to list on the NASDAQ under the symbol NERV. Minerva...read more
Minerva Neurosciences decreases proposed IPO deal size
Minerva Neurosciences, a clinical-stage biotech developing treatments for central nervous system diseases, lowered the proposed deal size for its upcoming IPO on Monday. The Cambridge, MA-based company now plans to raise $33 million by offering 5.5 million...read more
7 US IPOs planned for the week of Jun 30
The following IPOs are expected to price this week: Ambrx (AMBX), a biotech developing bio-conjugates to treat solid tumors and other diseases, plans to raise $70...read more